ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 42985635

Efficacy and Safety of Bioresorbable Vascular Scaffolds Versus Contemporary Drug-Eluting Stents in Coronary Artery Disease: A Systematic Review, Meta-Analysis, and Trial Sequential Analysis.

Yu Y and 6 others. Rev Cardiovasc Med, 2026.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Efficacy and Safety of Bioresorbable Vascular Scaffolds Versus Contemporary Drug-Eluting Stents in Coronary Artery Disease: A Systematic Review, Meta-Analysis, and Trial Sequential Analysis. Papers, record 42985635. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42985635

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Efficacy and Safety of Bioresorbable Vascular Scaffolds Versus Contemporary Drug-Eluting Stents in Coronary Artery Disease: A Systematic Review, Meta-Analysis, and Trial Sequential Analysis.
Journal
Rev Cardiovasc Med
Year
2026
Publication types
Journal Article, Systematic Review
Revised in PubMed
2026-11-06

Source PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Yu YYuehttps://orcid.org/0009-0004-5005-3861
2Shang KKehttps://orcid.org/0009-0006-9521-3042
3Jiao YYuemiaohttps://orcid.org/0009-0007-4366-6290
4Chang SSanshuaihttps://orcid.org/0000-0001-5589-9867
5Li YYanghttps://orcid.org/0000-0002-6973-1333
6Song GGuangyuanhttps://orcid.org/0000-0002-7868-6132
7Yin CChengqianhttps://orcid.org/0009-0009-9650-4978

Source PubMed

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References95

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
138,908,996Research Note: Trial sequential analysis in systematic reviews with meta-analysis.J Physiother2024https://conductscience.org/library/papers/38908996PubMed
237,226,676One- and two-year clinical outcomes of treatment with resorbable magnesium scaffolds for coronary artery disease: the prospective, international, multicentre BIOSOLVE-IV registry.EuroIntervention2023https://conductscience.org/library/papers/37226676PubMed
332,451,321Bioresorbable vascular scaffold versus metallic drug-eluting stent in patients at high risk of restenosis: the COMPARE-ABSORB randomised clinical trial.EuroIntervention2020https://conductscience.org/library/papers/32451321PubMed
424,909,303Comparison of early clinical outcomes between ABSORB bioresorbable vascular scaffold and everolimus-eluting stent implantation in a real-world population.Catheter Cardiovasc Interv2015https://conductscience.org/library/papers/24909303PubMed
526,597,771Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials.Lancet2016https://conductscience.org/library/papers/26597771PubMed
627,845,998Bioresorbable scaffolds compared with everolimus-eluting stents for the treatment of chronic coronary total occlusion: clinical and angiographic results of a matched paired comparison.Coron Artery Dis2017https://conductscience.org/library/papers/27845998PubMed
740,958,619Antithrombotic therapy in complex percutaneous coronary intervention.EuroIntervention2025https://conductscience.org/library/papers/40958619PubMed
840,238,640Drug-eluting resorbable coronary scaffolds: a review of recent advances.Expert Opin Drug Deliv2025https://conductscience.org/library/papers/40238640PubMed
932,881,396BIOSOLVE-IV-registry: Safety and performance of the Magmaris scaffold: 12-month outcomes of the first cohort of 1,075 patients.Catheter Cardiovasc Interv2021https://conductscience.org/library/papers/32881396PubMed
1026,457,558Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease.N Engl J Med2015https://conductscience.org/library/papers/26457558PubMed

1 to 10 of 95

See all 95 references

Cited by0

The papers in our copy of PubMed whose reference list names this one, newest first.

None in this release.

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42985635

GET https://conductscience.org/api/papers/v1/42985635/references?page=2

API referenceFor AI assistants